Frank Mottola - Nov 7, 2024 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
SVP, Quality, GMP, Ops, IT
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Stock symbol
SUPN
Transactions as of
Nov 7, 2024
Transactions value $
-$417,750
Form type
4
Date filed
11/8/2024, 04:13 PM
Previous filing
Feb 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $137K +15K +182.93% $9.13 23.2K Nov 7, 2024 Direct F1
transaction SUPN Common Stock Sale -$555K -15K -64.66% $36.98 8.2K Nov 7, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -15K -100% $0.00 0 Nov 7, 2024 Common Stock 15K $9.13 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an aggregate of 421 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2 The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.73 to $37.27. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F4 The option vested in four equal installments beginning on March 3, 2016.